MTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function

Journal of Immunology

Volumn 193, Issue 9, 2014, Pages 4477-4484

  Donnelly, Raymond P ^a   Loftus, Roísín M ^a   Keating, Sinéad E ^a   Liou, Kevin T ^b   Biron, Christine A ^b   Gardiner, Clair M ^a   Finlay, David K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOSE; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; POLYINOSINIC POLYCYTIDYLIC ACID; RAPAMYCIN; GRANZYME; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; GLUCOSE TRANSPORT; GLYCOLYSIS; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ENZYME ACTIVATION; GENE EXPRESSION; GLYCOLYSIS; GRANZYMES; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MULTIPROTEIN COMPLEXES; POLY I-C; TOR SERINE-THREONINE KINASES;

EID: 84908123523     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401558     Document Type: Article

References (42)

1. Powell, J. D., K. N. Pollizzi, E. B. Heikamp, and M. R. Horton. 2012. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30: 39-68.
2. Finlay, D. K., E. Rosenzweig, L. V. Sinclair, C. Feijoo-Carnero, J. L. Hukelmann, J. Rolf, A. A. Panteleyev, K. Okkenhaug, and D. A. Cantrell. 2012. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 209: 2441-2453.
3. Shi, L. Z., R. Wang, G. Huang, P. Vogel, G. Neale, D. R. Green, and H. Chi. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208: 1367-1376.
4. Kidani, Y., H. Elsaesser, M. B. Hock, L. Vergnes, K. J. Williams, J. P. Argus, B. N. Marbois, E. Komisopoulou, E. B. Wilson, T. F. Osborne, et al. 2013. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14: 489-499.
5. Amiel, E., B. Everts, T. C. Freitas, I. L. King, J. D. Curtis, E. L. Pearce, and E. J. Pearce. 2012. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J. Immunol. 189: 2151-2158.
6. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
7. Lee, S. H., M. F. Fragoso, and C. A. Biron. 2012. Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J. Immunol. 189: 2712-2716.
8. Bihl, F., J. Pecheur, B. Bréart, G. Poupon, J. Cazareth, V. Julia, N. Glaichenhaus, and V. M. Braud. 2010. Primed antigen-specific CD4+ T cells are required for NK cell activation in vivo upon Leishmania major infection. J. Immunol. 185: 2174-2181.
9. Kerdiles, Y., S. Ugolini, and E. Vivier. 2013. T cell regulation of natural killer cells. J. Exp. Med. 210: 1065-1068.
10. Neudoerfl, C., B. J. Mueller, C. Blume, K. Daemen, M. Stevanovic-Meyer, J. Keil, F. Lehner, H. Haller, and C. S. Falk. 2013. The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosup-pressive drugs. Front. Immunol. 4: 46.
11. Eissens, D. N., A. Van Der Meer, B. Van Cranenbroek, F. W. Preijers, and I. Joosten. 2010. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am. J. Transplant. 10: 1981-1990.
12. Nandagopal, N., A. K. Ali, A. K. Komal, and S. H. Lee. 2014. The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions. Front. Immunol. 5: 187.
13. Gil, M. P., M. J. Ploquin, W. T. Watford, S. H. Lee, K. Kim, X. Wang, Y. Kanno, J. J. O'Shea, and C. A. Biron. 2012. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood 120: 3718-3728.
14. Hinton, H. J., R. G. Clarke, and D. A. Cantrell. 2006. Antigen receptor regulation of phosphoinositide-dependent kinase 1 pathways during thymocyte development. FEBS Lett. 580: 5845-5850.
15. Caskey, M., F. Lefebvre, A. Filali-Mouhim, M. J. Cameron, J. P. Goulet, E. K. Haddad, G. Breton, C. Trumpfheller, S. Pollak, I. Shimeliovich, et al. 2011. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208: 2357-2366.
16. Pearce, E. L., and E. J. Pearce. 2013. Metabolic pathways in immune cell activation and quiescence. Immunity 38: 633-643.
17. Zhao, Y. M., and A. R. French. 2012. Two-compartment model of NK cell proliferation: insights from population response to IL-15 stimulation. J. Immunol. 188: 2981-2990.
18. Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517.
19. Koka, R., P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J. Immunol. 173: 3594-3598.
20. Dubois, S., J. Mariner, T. A. Waldmann, and Y. Tagaya. 2002. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 17: 537-547.
21. Masui, K., K. Tanaka, D. Akhavan, I. Babic, B. Gini, T. Matsutani, A. Iwanami, F. Liu, G. R. Villa, Y. Gu, et al. 2013. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 18: 726-739.
22. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22: 159-168.
23. Sukumar, M., J. Liu, Y. Ji, M. Subramanian, J. G. Crompton, Z. Yu, R. Roychoudhuri, D. C. Palmer, P. Muranski, E. D. Karoly, et al. 2013. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123: 4479-4488.
24. Frey, P. A. 1996. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J. 10: 461-470.
25. Chang, C. H., J. D. Curtis, L. B. Maggi, Jr., B. Faubert, A. V. Villarino, D. O'Sullivan, S. C. Huang, G. J. van der Windt, J. Blagih, J. Qiu, et al. 2013. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153: 1239-1251.
26. Michalek, R. D., V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell. 2011. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186: 3299-3303.
27. Wang, R., C. P. Dillon, L. Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L. L. McCormick, P. Fitzgerald, H. Chi, J. Munger, and D. R. Green. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35: 871-882.
28. Kim, S., K. Iizuka, H. S. Kang, A. Dokun, A. R. French, S. Greco, and W. M. Yokoyama. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3: 523-528.
29. Prlic, M., B. R. Blazar, M. A. Farrar, and S. C. Jameson. 2003. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197: 967-976.
30. Sun, J. C., J. N. Beilke, N. A. Bezman, and L. L. Lanier. 2011. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J. Exp. Med. 208: 357-368.
31. Orange, J. S., B. Wang, C. Terhorst, and C. A. Biron. 1995. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J. Exp. Med. 182: 1045-1056.
32. Sitrin, J., A. Ring, K. C. Garcia, C. Benoist, and D. Mathis. 2013. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J. Exp. Med. 210: 1153-1165.
33. Rolf, J., M. Zarrouk, D. K. Finlay, M. Foretz, B. Viollet, and D. A. Cantrell. 2013. AMPKa1: a glucose sensor that controls CD8 T-cell memory. Eur. J. Immunol. 43: 889-896.
34. Sinclair, L. V., J. Rolf, E. Emslie, Y. B. Shi, P. M. Taylor, and D. A. Cantrell. 2013. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14: 500-508.
35. Munger, J., B. D. Bennett, A. Parikh, X. J. Feng, J. McArdle, H. A. Rabitz, T. Shenk, and J. D. Rabinowitz. 2008. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26: 1179-1186.
36. Piccoli, C., G. Quarato, M. Ripoli, A. D'Aprile, R. Scrima, O. Cela, D. Boffoli, D. Moradpour, and N. Capitanio. 2009. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim. Biophys. Acta 1787: 539-546.
37. Ripoli, M., A. D'Aprile, G. Quarato, M. Sarasin-Filipowicz, J. Gouttenoire, R. Scrima, O. Cela, D. Boffoli, M. H. Heim, D. Moradpour, et al. 2010. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. J. Virol. 84: 647-660.
38. Hirayama, A., K. Kami, M. Sugimoto, M. Sugawara, N. Toki, H. Onozuka, T. Kinoshita, N. Saito, A. Ochiai, M. Tomita, et al. 2009. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69: 4918-4925.
39. Cham, C. M., and T. F. Gajewski. 2005. Metabolic mechanisms of tumor resistance to T cell effector function. Immunol. Res. 31: 107-118.
40. Carrega, P., B. Morandi, R. Costa, G. Frumento, G. Forte, G. Altavilla, G. B. Ratto, M. C. Mingari, L. Moretta, and G. Ferlazzo. 2008. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 112: 863-875.
41. Mamessier, E., A. Sylvain, M. L. Thibult, G. Houvenaeghel, J. Jacquemier, R. Castellano, A. Gonçalves, P. André, F. Romagné, G. Thibault, et al. 2011. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121: 3609-3622.
42. Platonova, S., J. Cherfils-Vicini, D. Damotte, L. Crozet, V. Vieillard, P. Validire, P. André, M. C. Dieu-Nosjean, M. Alifano, J. F. Régnard, et al. 2011. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71: 5412-5422.